Navigation Links
New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C)

adults) over a 12-week period.

Primary efficacy was determined by a unique question: "How would you rate your relief of IBS symptoms (abdominal discomfort/pain, bowel habits and other IBS symptoms) over the past week compared to how you felt before you entered the study?" A 7-point balanced scale with a strict evaluation using the two highest scale points to qualify as a responder was used. Patients were considered monthly responders if they reported at least moderate relief four out of four weeks or significant relief two out of four weeks. To qualify as an overall responder (the measure used in the primary endpoint), patients had to be a monthly responder for at least two out of three months. During the evaluation period, patients discontinuing for any reason or reporting an increase in rescue medication use, lack of efficacy or moderately or significantly worse relief were deemed non-responders. These responder rates may not be comparable to those in other studies since the new scale was more restrictive than those used in previous reports.

The findings demonstrated that patients receiving lubiprostone 8 mcg twice daily were nearly twice as likely to achieve overall response compared to those receiving placebo (lubiprostone 17.9 percent vs. placebo 10.1 percent, P=0.001). There was a similar incidence of serious adverse events (1 percent in each group) and related adverse events (lubiprostone 22 percent vs. placebo 21 percent) compared to placebo. The most common treatment-related adverse events (greater than or equal to 5% of patients) were nausea (8 percent vs. 4 percent, respectively), diarrhea (6 percent vs. 4 percent, respectively) and abdominal pain (4 percent vs. 5 percent, respectively).

About Irritable Bowel Syndrome with Constipation (IBS-C)

Irritable bowel syndrome (IBS) is a chronic disorder characterized by abdominal discomfort and pain, and bowel habit changes including symptoms of constipation and/or diarrhea. The condit
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:5/21/2013)... , May 21, 2013 /PRNewswire/ ... VRX ) (TSX: VRX) ... directors nominated at its 2013 annual ... results of the vote for the ... below:  NameForWithheldRonald H. Farmer235,731,9341,964,748Robert A. Ingram233,865,8763,830,806Theo ...
(Date:5/21/2013)... , May 21, 2013   Regulus Therapeutics ... leading the discovery and development of innovative medicines targeting ... , Ph.D., Chief Operating Officer and Executive Vice ... Deutsche Bank 38th Annual Healthcare Conference on Wednesday, May ... being held at the Westin Boston Waterfront Hotel. ...
(Date:5/21/2013)... , May 21, 2013 RenovoRx ( ... 2013 TiE50 "Top Startup" Award at TiEcon 2013, the ... strong management team and quality of entrepreneurial ideas. RenovoRx ... the Santa Clara Convention Center. ... influential list of the most enterprising startup companies across ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference 2RenovoRx Named Winner of 2013 TiE50 "Top Startup" 2
... 9, 2011 /PRNewswire-Asia/ -- Vaccines made in China ... agencies to developing countries, after recognition from the ... and Drug Administration (SFDA) has complied with international ... regulatory system is a precondition that could lead ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ... Court for the District of Massachusetts has granted ... Inc. for a temporary restraining order (TRO) preventing ... selling Amphastar,s Enoxaparin Sodium Injection product, a generic ...
Cached Medicine Technology:VacChina 2011 International Conference Meets in Shanghai This November 2Watson Confirms District Court Order Concerning Generic Version of LOVENOX(R) 2Watson Confirms District Court Order Concerning Generic Version of LOVENOX(R) 3
(Date:5/21/2013)... 2013 Octo Consulting Group, an ... consulting solutions to the Federal marketplace, has named ... In the newly created role, Denny will be ... the firm’s business development function to include business ... and leading strategies to achieve the firm’s strategic ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay ... steroid therapy for patients having severe bouts of chronic ... Five days of glucocorticoid treatment with prednisone to treat ... days, but with fewer chances for adverse side effects, ... shorter period of treatment was not less effective than ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) ... of sleep apnea in children, and while removing them ... kids, it did help them with sleep, behavior and ... apnea is a condition that causes abnormal pauses in ... in sleep with the surgery, and those improvements were ...
(Date:5/21/2013)... at high risk for developing lung cancer shows that ... helping clinicians spot tiny lung nodules which, in a ... of the disease. LDCT uses less than a quarter ... Results of the study will be presented at the ... leading cause of cancer-related death and has a poor ...
(Date:5/21/2013)... Mexican young adults may have a genetic predisposition for ... a study at the Universidad Autnoma de San Luis ... from both parents were already 15 pounds heavier and ... hadn,t. They also had slightly higher fasting glucose levels," ... food science and human nutrition. , In the study, ...
Breaking Medicine News(10 mins):Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2Health News:COPD Patients May Do Fine With Shorter Course of Steroids 2Health News:COPD Patients May Do Fine With Shorter Course of Steroids 3Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 2Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 3Health News:Low radiation scans help identify cancer in earliest stages 2Health News:Low radiation scans help identify cancer in earliest stages 3Health News:Genetic risk for obesity found in many Mexican young adults 2
... Treatment of heart patients no better after performance data released ... -- One might assume that public report cards ranking their ... study finds that isn,t the case. , Researchers found ... better job of treating heart patients after report cards were ...
... , ... November 16, 2009. , ... November 18, 2009 -- Ziosoft®, Inc. http://www.ziosoftinc.com -- a leader in advanced visualization ... vice president, sales and marketing, effective November 16., , , , ,Most recently, Royea served ...
... ... and Security Suite to deliver end-to-end endpoint management solution capabilities on a single ... ... 2009 -- Lumension , a global leader in endpoint management and security, ...
... Physicians for Social Responsibility today released a groundbreaking ... look at the devastating impacts of coal on the human body. ... organ systems of the human body, the report concludes that coal ... the U.S. and is responsible for increasing the incidence of major ...
... , MINEOLA, N.Y., Nov. 18 The United ... for when a woman should be getting a mammography. ... has made an official statement regarding her research and ... , Yesterday, The United States Preventive Services Task ...
... , BRIGHTON, Mass., Nov. 18 Sleep Health Centers ... US, is proud to announce the formation of SleepPartners ( ... accredited sleep centers with board-certified sleep specialists and a focus ... sleep programs combined with their geographic reach extends high quality ...
Cached Medicine News:Health News:Study Shows Hospital Report Cards Unlikely to Spur Improvement 2Health News:Ziosoft Announces the Appointment of Rob Royea, Vice President, Sales and Marketing 2Health News:Lumension Endpoint Management Platform Strategy to Reduce Complexity, Enhance Security & Compliance, and Expand Visibility across IT Operations and Security Functions 2Health News:Lumension Endpoint Management Platform Strategy to Reduce Complexity, Enhance Security & Compliance, and Expand Visibility across IT Operations and Security Functions 3Health News:Lumension Endpoint Management Platform Strategy to Reduce Complexity, Enhance Security & Compliance, and Expand Visibility across IT Operations and Security Functions 4Health News:Lumension Endpoint Management Platform Strategy to Reduce Complexity, Enhance Security & Compliance, and Expand Visibility across IT Operations and Security Functions 5Health News:Lumension Endpoint Management Platform Strategy to Reduce Complexity, Enhance Security & Compliance, and Expand Visibility across IT Operations and Security Functions 6Health News:Lumension Endpoint Management Platform Strategy to Reduce Complexity, Enhance Security & Compliance, and Expand Visibility across IT Operations and Security Functions 7Health News:Lumension Endpoint Management Platform Strategy to Reduce Complexity, Enhance Security & Compliance, and Expand Visibility across IT Operations and Security Functions 8Health News:Coal Pollution Damages Human Health at Every Stage of Coal Life Cycle, Reports Physicians for Social Responsibility 2Health News:Coal Pollution Damages Human Health at Every Stage of Coal Life Cycle, Reports Physicians for Social Responsibility 3Health News:Coal Pollution Damages Human Health at Every Stage of Coal Life Cycle, Reports Physicians for Social Responsibility 4Health News:Coal Pollution Damages Human Health at Every Stage of Coal Life Cycle, Reports Physicians for Social Responsibility 5Health News:Maurer Foundation for Breast Health Education Statement on USPSTF Guidelines for Mammography 2Health News:Sleep HealthCenters Launches SleepPartners(TM) Network 2
... An Antiseptic Antibacterial that does ... than 30 seconds, destroys over ... used for cleansing of minor ... for disinfection of personal utensils ...
... Bactericide, Microbicide for professional degerming, pre-op ... skin disinfectants combining quaternary and substituted ... blend of emollients and surfactants. Unprecedented ... organisms tested in 30 seconds. Techni-Care ...
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
... solution is for broad-spectrum germicidal ... is labeled for single use ... contamination. The controlled spray mist ... the final step of the ...
Medicine Products: